Polaris Group
Polaris Group, together with its subsidiaries, offers biotechnology, drug testing, and contract development and manufacturing services. The company engages in the research, development, manufacture and sale of new drugs. It develops ADI-PEG 20 for the treatment of various cancer indications, as well as provides healthcare consulting, staffing, and MDS solutions. The company was incorporated in 20… Read more
Polaris Group (6550) - Net Assets
Latest net assets as of September 2025: NT$4.19 Billion TWD
Based on the latest financial reports, Polaris Group (6550) has net assets worth NT$4.19 Billion TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$8.18 Billion) and total liabilities (NT$3.99 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$4.19 Billion |
| % of Total Assets | 51.22% |
| Annual Growth Rate | 51.53% |
| 5-Year Change | 134.97% |
| 10-Year Change | N/A |
| Growth Volatility | 174.2 |
Polaris Group - Net Assets Trend (2016–2024)
This chart illustrates how Polaris Group's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Polaris Group (2016–2024)
The table below shows the annual net assets of Polaris Group from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$6.77 Billion | -11.30% |
| 2023-12-31 | NT$7.63 Billion | -12.00% |
| 2022-12-31 | NT$8.67 Billion | +20.24% |
| 2021-12-31 | NT$7.21 Billion | +150.35% |
| 2020-12-31 | NT$2.88 Billion | -20.17% |
| 2019-12-31 | NT$3.61 Billion | +463.52% |
| 2018-12-31 | NT$640.55 Million | -35.98% |
| 2017-12-31 | NT$1.00 Billion | +310.70% |
| 2016-12-31 | NT$243.62 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Polaris Group's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 930659700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$7.70 Billion | 115.04% |
| Other Components | NT$13.56 Billion | 202.54% |
| Total Equity | NT$6.70 Billion | 100.00% |
Polaris Group Competitors by Market Cap
The table below lists competitors of Polaris Group ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nanjing Julong Science & Technology Co Ltd Class A
SHE:300644
|
$258.68 Million |
|
Shanghai Hollywave Electronic System Co. Ltd. A
SHG:688682
|
$258.74 Million |
|
Shenzhen KTC Technology Co. Ltd.
SHE:001308
|
$258.75 Million |
|
LX Holdings Corp. Pfd.
KO:38380K
|
$258.77 Million |
|
Netlist Inc
OTCQB:NLST
|
$258.58 Million |
|
Bank of Kaohsiung Ltd
TW:2836
|
$258.57 Million |
|
Fulcrum Therapeutics Inc
NASDAQ:FULC
|
$258.51 Million |
|
Hangzhou Shenhao Technology Co Ltd
SHE:300853
|
$258.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Polaris Group's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 7,366,027,000 to 6,695,414,000, a change of -670,613,000 (-9.1%).
- Net loss of 2,502,642,000 reduced equity.
- New share issuances of 1,223,529,000 increased equity.
- Other comprehensive income decreased equity by 1,085,130,999.
- Other factors increased equity by 1,693,630,999.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-2.50 Billion | -37.38% |
| Share Issuances | NT$1.22 Billion | +18.27% |
| Other Comprehensive Income | NT$-1.09 Billion | -16.21% |
| Other Changes | NT$1.69 Billion | +25.3% |
| Total Change | NT$- | -9.10% |
Book Value vs Market Value Analysis
This analysis compares Polaris Group's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.66x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 27.30x to 2.66x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | NT$0.87 | NT$23.85 | x |
| 2017-12-31 | NT$4.01 | NT$23.85 | x |
| 2018-12-31 | NT$2.22 | NT$23.85 | x |
| 2019-12-31 | NT$10.72 | NT$23.85 | x |
| 2020-12-31 | NT$4.41 | NT$23.85 | x |
| 2021-12-31 | NT$10.61 | NT$23.85 | x |
| 2022-12-31 | NT$11.84 | NT$23.85 | x |
| 2023-12-31 | NT$9.91 | NT$23.85 | x |
| 2024-12-31 | NT$8.95 | NT$23.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Polaris Group utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -37.38%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2338.92%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.36x
- Recent ROE (-37.38%) is above the historical average (-94.79%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -473.92% | 0.00% | 0.00x | 9.50x | NT$-1.00 Billion |
| 2017 | -89.79% | 0.00% | 0.00x | 2.22x | NT$-998.51 Million |
| 2018 | -161.15% | 0.00% | 0.00x | 3.08x | NT$-1.10 Billion |
| 2019 | -22.99% | 0.00% | 0.00x | 1.14x | NT$-1.19 Billion |
| 2020 | -22.91% | -7016.20% | 0.00x | 1.17x | NT$-948.38 Million |
| 2021 | -10.26% | -4923.12% | 0.00x | 1.08x | NT$-1.46 Billion |
| 2022 | -13.26% | -17866.64% | 0.00x | 1.06x | NT$-2.02 Billion |
| 2023 | -21.40% | -21075.98% | 0.00x | 1.24x | NT$-2.31 Billion |
| 2024 | -37.38% | -2338.92% | 0.01x | 1.36x | NT$-3.17 Billion |
Industry Comparison
This section compares Polaris Group's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Polaris Group (6550) | NT$4.19 Billion | -473.92% | 0.95x | $258.65 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |